Shakya, A. K., Chowdhury, M. Y. E., Tao, W. & Gill, H. S. Mucosal vaccine delivery: current state and a pediatric perspective. J. Control. Release 240, 394–413 (2016).
Alsbrooks, K. & Hoerauf, K. Prevalence, causes, impacts, and management of needle phobia: an international survey of a general adult population. PLoS ONE 17, e0276814 (2022).
Deuchert, E. & Brody, S. Lack of autodisable syringe use and health care indicators are associated with high HIV prevalence: an international ecologic analysis. Ann. Epidemiol. 17, 199–207 (2007).
Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592–605 (2012).
Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. eBioMedicine 75, 103788 (2022).
Kraan, H. et al. Buccal and sublingual vaccine delivery. J. Control. Release 190, 580–592 (2014).
Song, J.-H. et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105, 1644–1649 (2008).
McGhee, J. R. & Fujihashi, K. Inside the mucosal immune system. PLoS Biol. 10, e1001397 (2012).
Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148–158 (2006).
Paris, A. L., Colomb, E., Verrier, B., Anjuère, F. & Monge, C. Sublingual vaccination and delivery systems. J. Control. Release 332, 553–562 (2021).
Mokabari, K., Iriti, M. & Varoni, E. M. Mucoadhesive vaccine delivery systems for the oral mucosa. J. Dent. Res. 102, 709–718 (2023).
Shimono, M. et al. Biological characteristics of the junctional epithelium. J. Electron Microsc. 52, 627–639 (2003).
Bosshardt, D. D. & Lang, N. P. The junctional epithelium: from health to disease. J. Dent. Res. 84, 9–20 (2005).
Luke, D. A. The structure and functions of the dentogingival junction and periodontal ligament. Br. Dent. J. 172, 187–190 (1992).
Stern, I. B. Current concepts of the dentogingival junction: the epithelial and connective tissue attachments to the tooth. J. Periodontol. 52, 465–476 (1981).
Oh, C., Kim, H. J. & Kim, H. M. Transepithelial channels for leukocytes in the junctional epithelium. J. Periodontal Res. 57, 1093–1100 (2022).
Dutzan, N., Konkel, J. E., Greenwell-Wild, T. & Moutsopoulos, N. M. Characterization of the human immune cell network at the gingival barrier. Mucosal Immunol. 9, 1163–1172 (2016).
Boese, S. & Gill, H. S. Coated floss for drug delivery into the gum pocket. Int. J. Pharm. 606, 120855 (2021).
Subbarao, K. C. et al. Gingival crevicular fluid: an overview. J. Pharm. Bioallied Sci. 11, S135–S139 (2019).
Galli, S. J. & Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 18, 693–704 (2012).
Ainai, A., Suzuki, T., Tamura, S. I. & Hasegawa, H. Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate. Viral Immunol. 30, 451–462 (2017).
Seasonal flu vaccines. Centers for Disease Control and Prevention https://www.cdc.gov/flu/vaccines/keyfacts.html (2024).
Gresset-Bourgeois, V. et al. Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Exp. Rev. Vaccines 17, 1–11 (2018).
Haugh, M., Gresset-Bourgeois, V., Macabeo, B., Woods, A. & Samson, S. I. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Exp. Rev. Vaccines 16, 545–564 (2017).
Murdin, A. D., Barreto, L. & Plotkin, S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735–746 (1996).
Tao, Y. Y. et al. Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis. Exp. Rev. Vaccines 20, 1–11 (2021).
Vaccines licensed for use in the United States. US Food and Drug Administration https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states (2023).
Estrada, L. D. & Schultz-Cherry, S. Development of a universal influenza vaccine. J. Imunol. 202, 392–398 (2019).
Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza vaccine: different approaches for one goal. Virol. J. 15, 17 (2018).
Pica, N. & Palese, P. Toward a universal influenza virus vaccine: prospects and challenges. Ann. Rev. Med. 64, 189–202 (2013).
Taubenberger, J. K. & Morens, D. M. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12, 15–22 (2006).
Wang, W. C., Sayedahmed, E. E., Sambhara, S. & Mittal, S. K. Progress towards the development of a universal influenza vaccine. Viruses https://doi.org/10.3390/v14081684 (2022).
Tao, W., Ziemer, K. S. & Gill, H. S. Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine 9, 237–251 (2014).
Tao, W. et al. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. Antivir. Res. 141, 62–72 (2017).
Ingrole, R. S. J., Tao, W., Joshi, G. & Gill, H. S. M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets. Vaccine 39, 4800–4809 (2021).
Sjökvist Ottsjö, L. et al. Induction of mucosal immune responses against Helicobacter pylori infection after sublingual and intragastric route of immunization. Immunology 150, 172–183 (2017).
Liao, S. & von der Weid, P. Y. Lymphatic system: an active pathway for immune protection. Semin. Cell Dev. Biol. 38, 83–89 (2015).
Reichel, C. A. et al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler. Thromb. Vasc. Biol. 29, 1787–1793 (2009).
Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).
Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann. Rev. Immunol. 13, 251–276 (1995).
Liang, C. K. et al. COVID-19 vaccines in older adults: challenges in vaccine development and policy making. Clin. Geriatr. Med. 38, 605–620 (2022).
Baldwin, S. L. et al. Improved immune responses in young and aged mice with adjuvanted vaccines against H1N1 influenza infection. Front. Immunol. 9, 295 (2018).
García, M., Misplon, J. A., Price, G. E., Lo, C.-Y. & Epstein, S. L. Age dependence of immunity induced by a candidate universal influenza vaccine in mice. PLoS ONE 11, e0153195 (2016).
Kim, K.-H. et al. Immunogenicity and neutralizing activity comparison of SARS-CoV-2 spike full-length and subunit domain proteins in young adult and old-aged mice. Vaccines 9, 316 (2021).
Bang, Y. J. et al. Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant. Sci. Rep. 11, 11981 (2021).
Baldo, V. et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin. Dev. Immunol. 2010, 517198 (2010).
DiazGranados, C. A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Engl. J. Med. 371, 635–645 (2014).
Chahine, E. B. High-dose inactivated influenza vaccine quadrivalent for older adults. Ann. Pharmacother. 55, 89–97 (2021).
Mohan, T. et al. Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses. Sci. Rep. 7, 40226 (2017).
Keller, L.-A., Merkel, O. & Popp, A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res. 12, 735–757 (2022).
Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. New Engl. J. Med. 350, 896–903 (2004).
Boese, S. & Gill, H. S. Drug-coated floss to treat gum diseases: in vitro and in vivo characterization. ACS Appl. Mater. Interfaces 14, 28663–28670 (2022).
Chen, Y., Mutukuri, T. T., Wilson, N. E. & Zhou, Q. T. Pharmaceutical protein solids: drying technology, solid-state characterization and stability. Adv. Drug Deliv. Rev. 172, 211–233 (2021).
Amorij, J. P., Huckriede, A., Wilschut, J., Frijlink, H. W. & Hinrichs, W. L. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25, 1256–1273 (2008).
Chu, L. Y. et al. Enhanced stability of inactivated influenza vaccine encapsulated in dissolving microneedle patches. Pharm. Res. 33, 868–878 (2016).
Teeth development in children. Better Health Channel https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/teeth-development-in-children#rpl-skip-link (2021).
Kraan, H., Soema, P., Amorij, J.-P. & Kersten, G. Intranasal and sublingual delivery of inactivated polio vaccine. Vaccine 35, 2647–2653 (2017).
Tiwari, M. et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27, 2513–2522 (2009).
Uddin, M. J. & Gill, H. S. From allergen to oral vaccine carrier: a new face of ragweed pollen. Int. J. Pharm. 545, 286–294 (2018).
